Mental Disorders

274 trials 116 recruiting

Filter these 274 trials by phase, country and sponsor.

Open in Search →

A study in healthy women to test whether BI 1358894 influences the amount of a contraceptive in the blood Ended

2022-502861-78-00 Pharmacokinetic trial 3 2023-09-08
An Open-label, Single-dose, Parallel-group Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerabil… Ended

2022-502952-30-00 Healthy Adult Participants 3 2023-08-04
A rollover study for subjects that complete KAR-012 trial, to assess Long-term Safety and Tolerability of Adjunctive KarXT in Subjects with … Ended

2024-510773-20-00 Schizophrenia 5 2023-06-12
A study to evaluate if aticaprant added to a current antidepressant and given up to one year is safe and would help improve depression. Ended

2023-508163-74-00 Major Depressive Disorder 5 2023-06-12
Double-blind, randomized, monocentric study to evaluate the efficacy and safety of memantine in adolescents with Bipolar Disorder Ended

2024-516713-21-00 Bipolar Disorder 5 2023-06-09
SEMALCO Ended

2023-503371-25-00 Alcohol Use Disorder 4 2023-06-08
A study to evaluate the effect of multiple doses of carbamazepine on how long aticaprant (JNJ-67953964) stays in the body (pharmacokinetics)… Ended

2022-502951-77-00 Healthy Adult Participants 3 2023-05-05
Safety, tolerability and effect of DLX-001 in healthy volunteers Ended

2023-503390-38-00 Unipolar depression (UD) 1 2023-04-14
A randomized, double-blind, placebo-controlled, Phase 2b trial with an open-label extension to determine the safety and efficacy of GH001 in… Ended

2023-510047-37-00 Treatment-resistant depression (TRD) 4 2023-03-30
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) Ended

2024-510770-25-00 Schizophrenia 5 2023-03-22
Glucocorticoid enhancement of food exposure therapy in Binge Eating Disorder Ended

2024-515475-35-00 Binge Eating Disorder 4 2023-03-20
A 52-week, Open-label Trial of CVL-231 in Adult Participants With Schizophrenia Ended

2024-511441-19-00 Schizophrenia 4 2023-03-08
A Randomized, Double-Blind (Sponsor-Unblinded), Placebo-Controlled, Single And Multiple Ascending Dose Study To Evaluate Safety, Tolerabilit… Ended

2024-512987-74-00 Disorders characterized by a deficit in GABAergic signa 3 2023-02-27
A study to evaluate the long-term safety and tolerability of pimavanserin after 52 weeks of treatment in children and adolescents with ASD Ended

2024-512202-25-00 Irritability associated with autistic disorder in child 4 2023-02-27
AMIND - AMIloride for the treatment of Nephrogenic Diabetes insipidus for patients with bipolar disorder treated with lithium: a randomized … Ended

2024-515018-42-00 Patients treated with lithium carbonate for a bipolar d 4 2023-01-11
Treating Nightmares in Posttraumatic Stress Disorder with the α-adrenergic Agents Clonidine and Doxazosin: A Randomized-Controlled Feasibili… Ended

2024-517537-40-00 Posttraumatic Stress Disorder 4 2022-04-06
A study to test long-term safety of Iclepertin in people with schizophrenia who took part in a previous CONNEX study Ended

2024-511560-93-00 Schizophrenia 5 2022-03-29
Nitrous Oxide in Resistant Depression in Elderly Subjects: A Randomized, Double-blind, Comparator Trial Ended

2024-517549-15-00 Resistant Depression in the Elderly Subject 5 2021-11-16
Effects of the appetite-inducing hormone ghrelin on decision making in healthy volunteers Ended

2024-517598-26-00 Gambling disorder 4 2019-08-26
Cerebral neuroinflammation during major depressive episode: multicentric comparative study (InflaDep) Ended

2024-518405-18-00 Depressive disorder 6 2018-12-07
Exploring the Pharmacomicrobiomics of Depression Ended

2024-518101-18-02 Major Depressive Disorder 6
A Double-Blind, Oral, Placebo-Controlled, Multiple-Dose, Parallel, Randomized Study to Evaluate Efficacy and Safety of Endoxifen in Bipolar … Ended

2024-511829-57-00 Bipolar I Disorder 5
A Phase 2 Trial Evaluating the Effects of Thiethylperazine as diagnostic tool and therapeutic agent in Patients Diagnosed with an Early Stag… Ended

2022-501137-23-00 Newly diagnosed early-to-mild dementia due to Alzheimer 4
A study to evaluate the effect of multiple doses of carbamazepine and itraconazole on how long JNJ-55308942 stays in the body (pharmacokinet… Ended

2023-504055-27-00 Bipolar depression 3